Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misrepresenting information regarding its drug AMT-130 during a specific class period, leading to significant stock price decline [1]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [1]. Legal Allegations - The lawsuit claims that uniQure misrepresented the FDA approval status of its Pivotal Study for AMT-130 and downplayed the potential delay in its Biologics License Application (BLA) timeline [1]. - The complaint highlights that the FDA did not agree that the Phase I/II data could serve as primary evidence for a BLA submission, causing uncertainty regarding the submission timeline [1]. Stock Performance Impact - Following the disclosure on November 3, 2025, uniQure's stock plummeted over 49%, dropping from $67.69 per share on October 31, 2025, to $34.29 per share the next trading day [1].

Core Viewpoint - Viewbix Inc. is strategically acquiring Quantum X Labs to enhance its position in the quantum technology sector, targeting various applications and leveraging Israel's academic strengths in the field [1] Acquisition Details - Viewbix signed a definitive agreement to acquire 85-100% of Quantum X Labs, with completion expected within 90 days, pending due diligence and regulatory approvals [1] - The acquisition includes Quantum X Labs' expanding patent portfolio, particularly in quantum error correction [1] Financial Aspects - A private placement financing was amended in early January 2026, involving 800,000 units at approximately $1.75, raising about $1.4 million gross, with an additional potential of up to $1.68 million in warrants [1] - Majority stockholder written consent was secured on January 5, 2026, and a definitive Schedule 14C was filed with the SEC on January 15, 2026 [1] Quantum X Labs' Portfolio - Quantum X Labs is developing several key technologies: - Nuclear Quantum focuses on reactor simulation and materials science [1] - QuantumQ Security aims to protect data and infrastructure [1] - Quantum Aton Accuracy leverages quantum principles for precision applications [1] - Cliniquantum is working on drug discovery methods using quantum-enhanced techniques [1] - Quantum Transportation addresses scalability issues in quantum computing [1] - Quantum Gyro is developing technology for GPS-denied environments [1] Market Position and Ecosystem - Quantum X Labs is positioned to tap into significant near-term total addressable markets (TAMs) in navigation, precision timing, security, and nuclear simulation [1] - The company benefits from Israel's elite university ecosystem, which provides a talent edge and fosters interdisciplinary collaboration [1]

S.A. de C.V. of Hermosillo, Sonora, Mexico.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Qualified PersonsThe mineral resource was estimated by Ben Eggers, MAIG, P.Geo. of SGS Geological Services, an independent Qualified Person as defined by NI 43-101. Eggers conducted a site visit to the Columba Property on May 28, 2025. The mineral resource was peer ...

SÃO PAULO, Feb. 23, 2026 AZUL S.A. (B3: AZUL53; OTC: AZULQ) ("Azul" or "Company"), the largest airline in Brazil in number of cities served and direct domestic routes, today announced the appointment of John S. Slattery to its Strategy Committee, effective February 20, 2026. John joins Azul at a pivotal moment as the Company finalizes its emergence from its Chapter 11 process, bringing decades of global leadership experience in the aerospace and aviation industries. Azul S.A. (B3: AZUL53; OTC: AZULQ), the l ...

Core Insights - CNO Financial Group recognized associate Stacy Muentzer Oakey as Volunteer of the Year and announced donations to 12 nonprofits through its Invested in Giving Back® program [1] Group 1: Volunteer Recognition - Stacy Muentzer Oakey was honored for her dedicated service to Scouting America's Pathway to Adventure Council, receiving a $10,000 donation for the organization [1] - In 2025, Muentzer Oakey contributed over 410 hours of service, including 16 nights of camping and more than 1,500 miles of travel for Scout events [1] - The recognition reflects her significant impact on Troop 216 and sets a standard for volunteer service within the organization [1] Group 2: Invested in Giving Back Program - CNO's Invested in Giving Back program, now in its eighth year, allows associates to nominate and vote for community programs to receive charitable donations [1] - This year, CNO will donate a total of $180,000 across 12 nonprofit organizations [1] - The program exemplifies CNO's commitment to community support and empowers associates to influence corporate philanthropy [1] Group 3: Company Overview - CNO Financial Group, Inc. provides life and health insurance, annuities, and financial services, securing the future of middle-income America [1] - The company manages 3.2 million policies and has total assets of $38.8 billion [1] - CNO employs 3,300 associates and collaborates with 5,000 exclusive agents and over 7,000 independent partner agents [1]

launched or updated products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports ...

Core Points - The Corcept Therapeutics class action lawsuit seeks to represent investors who purchased common stock between October 31, 2024, and December 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1] - The lawsuit claims that Corcept misrepresented the support for its relacorilant New Drug Application (NDA), suggesting it was close to FDA approval despite known concerns from the FDA regarding clinical evidence [1] - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the relacorilant NDA, leading to a more than 50% drop in the company's stock price [1] - The FDA's CRL indicated that the clinical studies submitted were insufficient to demonstrate relacorilant's efficacy, and the FDA had previously warned Corcept about significant review issues [1] Company Overview - Corcept Therapeutics is engaged in the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with relacorilant being a lead candidate for treating hypercortisolism [1] - The company has faced significant scrutiny regarding the adequacy of its clinical development program for relacorilant, which has implications for its future product approvals and market performance [1] Legal Context - The Private Securities Litigation Reform Act of 1995 allows investors who suffered losses during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [1] - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1]

Real-time financial crimes platform improves risk visibility, accelerates fraud investigations, strengthens member protection MONETT, Mo., Feb. 23, 2026 /PRNewswire/ -- ®Jack Henry (Nasdaq: JKHY) announced today that SELCO Community Credit Union (SELCO) is leveraging Jack Henry Financial Crimes Defenderâ"¢, the company's fraud and anti-money laundering (AML) solution designed with real-time capabilities, to modernize its defense strategy with greater efficiency across the organization. Founded in 1936 by a ...

platform designed to support employees at every stage of their financial journey. To learn more, please visit [https://enterprise.chime.com/].Media Contact: [[email protected]]Chime is a financial technology company, not a bank. Banking services provided by The Bancorp Bank, N.A. or Stride Bank, N.A., Members FDIC. The secured Chime Visa® Credit Card is issued by The Bancorp Bank, N.A. or Stride Bank, N.A., pursuant to a license from Visa U.S.A. Inc.Chime Workplace offered by Chime. Banking services provide ...

Core Insights - Toyota and Lexus have partnered with Treehouse to simplify the installation of home EV chargers for their customers, enhancing the ownership experience of battery electric vehicles (BEVs) and plug-in hybrid vehicles (PHEVs) [1] Group 1: Home Charging Solutions - Treehouse provides a comprehensive home installation process for Level 2 AC charging, managing everything from project scoping to installation in a single visit [1] - Customers can receive installation quotes within 48 hours using Treehouse's virtual scoping technology, which requires minimal input [1] - The collaboration aims to make home charging as easy and enjoyable as owning a Toyota or Lexus vehicle [1] Group 2: Charging Equipment and Features - All 2026 and newer Toyota and Lexus BEVs and PHEVs come with a dual-voltage 120V/240V AC home charger, allowing for both Level 1 and Level 2 charging [1] - The dual-voltage charging cable can charge a vehicle from approximately 10% to full capacity overnight under ideal conditions, with a maximum output of 7.7 kW [1] - A hardwired ChargePoint Home Flex Level 2 charger is also available, which can reduce charging time by up to 30% depending on the vehicle and setup [1] Group 3: Company Background - Toyota has been a significant player in North America for nearly 70 years, employing around 64,000 people and contributing to the design and assembly of nearly 49 million vehicles [1] - Treehouse has raised over $25 million in financing to support its mission of simplifying the electrification journey for various stakeholders [1]